April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Anti-Inflammatory Activity of Topical Azithromycin Ophthalmic Solution 1% in the Treatment of Ocular Inflammation
Author Affiliations & Notes
  • Z. Sadrai
    Ophthalmology/Harvard Med Sch, Schepens Eye Research Institute, Boston, Massachusetts
  • A. R. Hajrasouliha
    Ophthalmology/Harvard Med Sch, Schepens Eye Research Institute, Boston, Massachusetts
  • S. Chauhan
    Ophthalmology/Harvard Med Sch, Schepens Eye Research Institute, Boston, Massachusetts
  • D. Saban
    Ophthalmology/Harvard Med Sch, Schepens Eye Research Institute, Boston, Massachusetts
  • R. Dana
    Ophthalmology/Harvard Med Sch, Schepens Eye Research Institute, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Z. Sadrai, None; A.R. Hajrasouliha, None; S. Chauhan, None; D. Saban, None; R. Dana, None.
  • Footnotes
    Support  Research support from Inspire Pharmaceuticals (R. Dana)
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3789. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Z. Sadrai, A. R. Hajrasouliha, S. Chauhan, D. Saban, R. Dana; Anti-Inflammatory Activity of Topical Azithromycin Ophthalmic Solution 1% in the Treatment of Ocular Inflammation. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3789.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the potential anti-inflammatory effects of AZM on corneal inflammation.

Methods: : Murine corneal inflammation was induced by thermal cautery. Corneas were treated topically either with AZM ophthalmic solution 1% (AzaSite®; Inspire Pharmaceuticals, Inc, NC, USA), prednisolone acetate 1% or relevant vehicles, twice per day. Corneas were harvested on days 1, 3, and 7 to characterize the inflammatory infiltrates via FACS analysis and to quantitate and analyze relevant chemokines/cytokines and intercellular adhesion molecule (ICAM-1) via real time PCR.

Results: : Relative to the vehicle control, the AZM-treated group showed a significant reduction in total infiltration of CD45+ (pan-leukocyte marker) cells at early time points (i.e. day 1) by 30% and later time points (i.e. day 7) by 39%, which was similarly observed in the prednisolone-treated group. Specifically, we observed a 6% reduction in macrophages (CD11b+) at later time points in the AZM-treated and 16% reduction in the prednisolone-treated groups. Moreover, dendritic cells (CD11c+) demonstrated a 35% reduced infiltration at later time points in the AZM-treated and a 40% reduction in the prednisolone-treated groups. ICAM-1 expression in the AZM-treated group reduced by two-fold at day 7.

Conclusions: : Following an inflammatory insult, topical AZM considerably reduces the leukocyte infiltration into the cornea at levels comparable to the prednisolone-treated group. This was further supported by an associated decrease in expression of ICAM-1 in the cornea in the AZM-treated eyes. This indicates that AZM may have a potential anti-inflammatory effect on corneal inflammation.

Keywords: cornea: basic science • immunomodulation/immunoregulation • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×